International Flavors & Fragrances Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
IFF is a global creator and manufacturer of food, beverage, health and biosciences, scent, pharmaceutical and related ingredients. The filing covers the unaudited three months ended March 31, 2024, compared with the three months ended March 31, 2023. Reportable segments are Nourish, Health & Biosciences, Scent and Pharma Solutions.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $2.899 billion | $3.027 billion | Down 4%; down 1% currency-neutral |
| Gross profit | $1.024 billion | $964 million | Up 6% |
| Gross margin | 35.3% | 31.8% | Up 350 basis points |
| Operating profit | $199 million | $131 million | Up 52% |
| Operating margin | 6.9% | 4.3% | Up 260 basis points |
| Net income attributable to IFF shareholders | $60 million | $(9) million | Improved |
| Diluted EPS | $0.23 | $(0.04) | Improved |
| Segment Adjusted Operating EBITDA | $578 million | $503 million | Up 15%; margin 19.9% versus 16.6% |
| Operating cash flow | $99 million | $127 million | Down 22% |
| Capital expenditures | $118 million | $175 million | Down 33% |
Sales were pressured by approximately $153 million from prior divestitures and by unfavorable foreign exchange, partly offset by volume and price increases. Gross profit benefited from productivity gains, favorable net pricing, lower raw-material and manufacturing costs, and portfolio changes.
- Nourish sales declined 9% reported and 6% currency-neutral; Segment Adjusted Operating EBITDA increased to $216 million from $208 million.
- Health & Biosciences sales increased 4% reported and 6% currency-neutral; EBITDA increased to $159 million from $131 million.
- Scent sales increased 6% reported and 12% currency-neutral; EBITDA increased to $157 million from $105 million.
- Pharma Solutions sales declined 10% reported and 11% currency-neutral; EBITDA declined to $46 million from $59 million.
Cash, cash equivalents and restricted cash totaled $771 million at March 31, 2024, compared with $735 million at December 31, 2023. Management separately reported $764 million of cash and cash equivalents including $32 million classified within assets held for sale. Trade receivables were $1.977 billion and inventories were $2.411 billion.
Total debt was $10.298 billion on the balance sheet, including $836 million of commercial paper and $250 million drawn on the revolving credit facility. Long-term debt was $9.150 billion. The company reported $1.791 billion of available revolving-credit capacity and a net debt-to-credit-adjusted-EBITDA covenant ratio of 4.42x, versus a 5.25x applicable covenant threshold at March 31, 2024. The company was in compliance with its covenants.
Financing activities generated $40 million, including $833 million of net commercial-paper borrowings, $250 million of revolving-facility borrowings, $833 million of long-term debt repayments and $207 million of dividends paid. In early April 2024, the company repaid $586 million of commercial paper and $250 million on the revolving facility, primarily using proceeds from the Cosmetic Ingredients divestiture.
Material changes versus the prior comparable period
- Net income attributable to shareholders improved from a $9 million loss to $60 million of income, primarily reflecting higher gross profit, lower restructuring costs, lower interest expense and lower other expense.
- Interest expense declined to $83 million from $100 million, while other expense declined to $1 million from $17 million.
- Restructuring and other charges fell to $3 million from $52 million.
- Selling and administrative expense increased 8% to $490 million, driven substantially by higher legal, investigation-related and professional fees.
- Operating cash flow decreased because of higher working-capital use, particularly accounts receivable.
- Foreign currency translation produced a $293 million loss in other comprehensive income, compared with a $284 million gain in Q1 2023, causing comprehensive income attributable to shareholders to change from $273 million of income to a $235 million loss.
- The company corrected certain prior-period presentation amounts, revising Q1 2023 interest expense from $111 million to $100 million, other expense from $6 million to $17 million, and receivables factored from $445 million to $402 million.
Guidance, outlook, commentary and risks
Management expects 2024 capital spending to be approximately 4.9% of sales, net of potential grants and reimbursements, compared with 4.1% in 2023. The filing does not provide a clear numeric full-year sales or profit guidance figure. Management expects operating cash flows, planned divestiture proceeds and available credit facilities to fund operations, capital investments, dividends and debt service.
IFF completed the sale of its Cosmetic Ingredients business on April 2, 2024 and received approximately $841 million of gross proceeds, subject to final closing adjustments. The company also agreed to sell its Pharma Solutions business for a value of up to $2.85 billion; closing is expected in the second quarter of 2025 and remains subject to customary conditions.
The effective tax rate was 47.0%, primarily due to business-divestiture tax expenses, earnings mix and jurisdictions with valuation allowances. Unrecognized tax benefits were approximately $128 million, accrued interest and penalties were approximately $48 million, and aggregate uncertain tax positions including interest and penalties were approximately $176 million.
Key risks include substantial indebtedness, leverage and refinancing costs; foreign-exchange volatility; inflation and raw-material, energy and logistics costs; working-capital requirements; geopolitical events affecting Russia, Ukraine and the Middle East; competition and customer demand; impairment of goodwill and intangible assets; execution of divestitures and the strategic transformation; litigation and regulatory investigations involving the fragrance businesses; tax disputes; product, environmental and compliance matters; and cybersecurity risks.
The company recognized approximately $35 million of regulatory costs in the segment reconciliation, primarily related to legal fees and provisions associated with ongoing fragrance-business investigations. The filing states that the duration and outcome of the investigations by the European Commission, U.K. Competition and Markets Authority, U.S. Department of Justice and Swiss Competition Commission cannot currently be predicted.
Important facts for investors to verify
- Confirm the final proceeds, adjustments and debt repayment effects from the Cosmetic Ingredients sale.
- Track the timing, purchase price, conditions and leverage implications of the planned Pharma Solutions divestiture.
- Assess whether improved gross and segment margins are sustainable after portfolio changes and normalization of pricing, volumes and input costs.
- Monitor commercial paper balances, revolving-facility utilization, covenant thresholds and upcoming maturities, particularly the 2025 notes.
- Review the outcome and potential financial exposure from fragrance-business antitrust investigations and related litigation.
- Reconcile reported cash balances, including cash classified as held for sale, and monitor working-capital trends and receivables factoring.
- Evaluate the effect of foreign-exchange movements on earnings, equity and the $1.4 billion notional cross-currency swap portfolio.